AI research is central to many of the deals. In April, French pharmaceutical giant Sanofi announced a $1.7 billion agreement ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

AstraZeneca (NASDAQ:AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC). As part of the deal, AstraZeneca will pay ...

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

On June 13, AstraZeneca PLC (NASDAQ:AZN) announced that it had entered into a strategic research collaboration with CSPC Pharmaceuticals Group Limited, based in Shijiazhuang City.

AstraZeneca said it would have access to CSPC's pre-clinical candidate small molecule - YS2302018 - an oral Lp (a) disruptor, with the aim to develop it as a lipid-lowering therapy.

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp (a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise ...

CSPC said the compound was discovered by the Group's AI-driven small molecule drug design platform. AstraZeneca's London-listed shares slipped 0.2% on Monday but have gained 11% this year.

0347 ET – CSPC Pharmaceutical looks set to benefit from an exclusive licensing agreement with AstraZeneca to develop and commercialize a pre-clinical lipid-lowering drug compound, Nomura ...

AstraZeneca (NASDAQ: AZN) is looking to boost its cardiovascular pipeline through an exclusive license agreement with CSPC Pharmaceutical Group (CSPC). As part of the deal, AstraZeneca will pay ...